Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
Natura:	Articolo
Lingua:	English
Pubblicazione:	Wiley 2021-08-01
Serie:	ACR Open Rheumatology
Accesso online:	https://doi.org/10.1002/acr2.11259

Documenti analoghi

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
di: Tore K Kvien, et al.
Pubblicazione: (2019-05-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
di: Vivian P. Bykerk, et al.
Pubblicazione: (2023-02-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
di: Jeffrey R. Curtis, et al.
Pubblicazione: (2017-12-01)

Certolizumab pegol in the treatment of spondyloarthritis
di: Mariusz Korkosz
Pubblicazione: (2014-09-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
di: Sh. F. Erdes
Pubblicazione: (2016-02-01)

Certolizumab pegol in therapy for rheumatoid arthritis
di: Galina Viktorovna Lukina, et al.
Pubblicazione: (2012-06-01)

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
di: Marie de Bourayne, et al.
Pubblicazione: (2022-02-01)

Quantitation of certolizumab pegol by validated liquid chromatography methods
di: Clóvis Dervil Appratto Cardoso Júnior, et al.
Pubblicazione: (2023-11-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
di: T. V. Korotaeva, et al.
Pubblicazione: (2015-10-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
di: Mehmet Baysal, et al.
Pubblicazione: (2018-09-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
di: M Connock, et al.
Pubblicazione: (2010-10-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
di: Lindsey J. Wanberg, et al.
Pubblicazione: (2024-06-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
di: Smolen, JS, et al.
Pubblicazione: (2024)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
di: Stéphane Paul, et al.
Pubblicazione: (2020-07-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
di: Ruiz Garcia, V, et al.
Pubblicazione: (2011)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
di: Ruiz Garcia, V, et al.
Pubblicazione: (2014)

Experience with long-term use of certolizumab pegol (Cimzia)
di: Karine Arnoldovna Lytkina, et al.
Pubblicazione: (2013-10-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
di: I.L. Khalif, et al.
Pubblicazione: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
di: Ranatunga S, et al.
Pubblicazione: (2014-02-01)

Experience with long-term use of certolizumab pegol (Cimzia)
di: Karine Arnoldovna Lytkina, et al.
Pubblicazione: (2013-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
di: Maria Majdan, et al.
Pubblicazione: (2014-07-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
di: Piotr Wiland, et al.
Pubblicazione: (2011-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
di: P. I. Novikov, et al.
Pubblicazione: (2018-07-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
di: Vera Nikolayevna Amirdjanova, et al.
Pubblicazione: (2012-10-01)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
di: A. Spadaro, et al.
Pubblicazione: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
di: Wojciech Blonski, et al.
Pubblicazione: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
di: O V Knyazev, et al.
Pubblicazione: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
di: Yael Sharon, et al.
Pubblicazione: (2020-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
di: Tanaka, Y, et al.
Pubblicazione: (2023)

Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report
di: Paolo Gisondi, et al.
Pubblicazione: (2025-01-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
di: Evgeniy L'vovich Nasonov, et al.
Pubblicazione: (2011-02-01)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
di: Nouf Almuhanna, MD, et al.
Pubblicazione: (2023-09-01)

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
di: A. A. Kubanov, et al.
Pubblicazione: (2019-12-01)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
di: Henry Alistair I, et al.
Pubblicazione: (2011-11-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
di: R. Talotta, et al.
Pubblicazione: (2016-09-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
di: Emna Hannech, et al.
Pubblicazione: (2021-06-01)

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study
di: Louis Bessette, et al.
Pubblicazione: (2019-03-01)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
di: Pablo Coto-Segura, et al.
Pubblicazione: (2023-09-01)

Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases
di: Denis Menshykau, et al.
Pubblicazione: (2024-11-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
di: Dmitry Evgenyevich Karateev, et al.
Pubblicazione: (2012-04-01)